Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG1805 in relapsed/refractory Acute Myeloid Leukemia
NCT06118788Phase 2Recruiting
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Autologous anti-CLL-1 CAR T lymphocytes BG1805 in acute myeloid leukemia (AML), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Dose Limited Toxicity Rate at 28 days and Incidence of Treatment-Emergent Adverse Events at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
Autologous anti-CLL-1 CAR T lymphocytes BG1805
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06118788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118788.